A prodrug targeting CIM6P/IGF2R enhances memory in healthy mice and reverses deficits in an Angelman syndrome mouse model.

ABSTRACT: Devastating diseases of the central nervous system (CNS), such as neurodevelopmental disorders and neurodegenerative diseases, carry severe neurological symptoms, including cognitive impairment -a decline characterized by learning and memory problems. Currently, no efficacious treatment is available for preventing or treating these diseases; therefore, there is a great unmet need to find novel, effective therapeutics. Previous studies have shown that insulin-like growth factor 2 (IGF2) and mannose 6-phosphate (M6P), two major ligands of the cation-independent M6P/IGF2 receptor (CIM6P/IGF2R), significantly enhance memory and prevent forgetting in healthy animals. Furthermore, they reverse most core symptoms in mouse models of neurodevelopmental disorders, such as Angelman syndrome (AS mice)

SUBMITTER: Aria F 

PROVIDER: S-EPMC12575744 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature